| Literature DB >> 18579402 |
Richard P Chalwin1, Ravindranath Tiruvoipati, Giles J Peek.
Abstract
Bleeding remains a potential complication for patients requiring extracorporeal life support systems. Recombinant activated factor VII (rFVIIa) is one of the drugs used in controlling bleeding. Its use is generally found to be safe. We report a paediatric patient who developed fatal thrombosis with the use of rFVIIa whilst on extracorporeal membrane oxygenation and discuss the possible factors that lead to fatal thrombosis.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18579402 DOI： 10.1016/j.ejcts.2008.05.022
Source DB: PubMed Journal: Eur J Cardiothorac Surg ISSN： 1010-7940 Impact factor: 4.191